Darunavir: In treatment-experienced pediatric patients with HIV-1 infection

Pediatric Drugs

Volumn 12, Issue 2, 2010, Pages 123-131

  McKeage, Kate ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Children; Darunavir, adverse reactions; Darunavir, pharmacodynamics; Darunavir, pharmacokinetics; Darunavir, therapeutic use; HIV infections

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATORVASTATIN; CARBAMAZEPINE; CLARITHROMYCIN; DARUNAVIR; DIDANOSINE; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; FLUTICASONE PROPIONATE; INDINAVIR; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR; SERTRALINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CELL CULTURE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; INFESTATION; LOW DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG SYNERGISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RITONAVIR; SULFONAMIDES;

EID: 77949435859     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11204530-000000000-00000     Document Type: Review

References (39)

1. Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis 2009 Jun; 22 (3): 256-263
2. Working Group on Antiretroviral Therapy andMedical Management of HIVInfected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http://aidsinfo.nih.gov/ Content Files/PediatricGuidelines.pdf [Accessed 2009 Nov 24]
3. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009; 69 (4): 477-503
4. Koh Y, Nakata H, Maeda K, et al. Novel bis- tetrahydrofuranylurethanecontaining nonpeptide protease inhibitor (PI) IUC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3123-3129
5. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitorresistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2314-2321
6. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 2009 Aug 30; 23 (15): 2005-2013
7. Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007 Sep 28; 282 (39): 28709-28720
8. KingNM,Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004 Nov; 78 (21): 12012-12021
9. EuropeanMedicines Agency. Prezista- film coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/EPAR [Accessed 2009 Nov 17]
10. Tibotec Therapeutics. Prezista- (darunavir) tablet. Full prescribing information [online]. Available from URL: http://www.prezista.com/prezista/ documents/ us-package-insert.pdf [Accessed 2009 Nov 3]
11. Dierynck I, De WitM, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007 Dec; 81 (24): 13845-13851
12. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23 (14): 1829-1840
13. Lathouwers E, De Meyer S, Dierynck I, et al. Update on the prevalence of the 2007 darunavir resistance-associated mutations in samples received for routine clinical resistance testing [abstract plus poster]. 6th European HIV Drug Resistance Workshop; 2008 Mar 26-28; Budapest
14. Thuret I, Chaix M-L, Tamalet C. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009; 23 (17): 2364-2366
15. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008; 13 (1): 1-13
16. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.Antivir Ther 2007; 12 (4): 509-514
17. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers. Intervirol. In press
18. Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir [abstract no. A-367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
19. Sekar VJ, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007 Dec; 29 (6): 795-801
20. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008 Jan; 48 (1): 60-65
21. Sekar VJ, Lefebvre E, De Pauw M, et al. Pharmacokinetics of darunavir/ ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008 May 5; 66 (2): 215-221
22. Sekar V, De Paepe E, DeMarez T, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline [abstract no. P295 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow
23. Sekar VJ, Lavreys L, De Paepe E, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin [abstract no. H-4053]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28; Washingon, DC
24. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract no. 54]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18; Budapest
25. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8 (4): 241-248
26. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract]. 4th International AIDS Society Conference; 2007 Jul 22-25; Sydney
27. Mathias AA, Hinkle J, Shen G, et al. Effect of ritonavir boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 2008; 49 (2): 156-162
28. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12 (5): 789-796
29. Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2009; 68 (1): 116-119
30. Hoetelmans RMW, Mariën K,De PauwM, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007 Nov; 64 (5): 655-661
31. Madruga JV, Berger D, McMurchieM, et al. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatmentexperienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 Jul 7; 370 (9581): 49-58
32. Clotet B, BellosN,Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection inPOWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 Apr 7; 369 (9568): 1169-1178
33. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007 Sep; 46 (1): 24-31
34. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Ther 2009; 14 (6): 859-864
35. Pozniak A, Arasteh K, Molina JM, et al.POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatmentexperienced HIV patients [abstract no. P24 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
36. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144- week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg bid in treatment-experienced HIV patients [abstract no. P21 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
37. Sekar VJ, Lavreys L, De Paepe E, et al. Bioavailability and food effect of darunavir (DRV) following administration of an oral suspension [abstract no. H233]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
38. Tibotec Pharmaceuticals, Ireland. TMC114-TiDP29-C228: a safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (RTV) in HIV-1 infected children from 3 years to below 6 years of age [ClinicalTrials.gov identifier NCT00919854]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinical trials.gov [Accessed 2010 Jan 12]
39. Tibotec Pharmaceuticals, Ireland. TMC114-TiDP29-C230: a safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV-1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugs [ClinicalTrials.gov identifier NCT00915655]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Jan 12]